Clinical Trials
3 trialsNCT05002569 2026-01-08
RELATIVITY-098
Bristol-Myers Squibb
Phase 3 Terminated
NCT03978611 2024-07-24
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
Bristol-Myers Squibb
Phase 1 Terminated
NCT03724968 2021-04-20
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated